Filiz Oezkan, MD, University Hospital Essen, Essen, Germany, provides an overview into an analysis of the Phase II LCMC3 (NCT02927301) trial of neoadjuvant atezolizumab in early-stage non-small cell lung cancer (NSCLC), exploring the impact of T-cell dynamics in the tumor and peripheral blood in association with pathologic response. Tumor, blood and lymph node samples were taken prior to treatment and after 2 cycles at surgery. Neoadjuvant atezolizumab in early-stage NSCLC increased specific T-cell clone expansion in the tumor compared with pre-treatment, which was associated with better pathologic response. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.